ArticleBMC psychiatry2025
METS-IR and SII as mediators in the association between smoking and depressive symptoms: insights from NHANES (2005-2018).
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic immune-inflammation index predicts hemorrhagic transformation after endovascular therapy for ischemic stroke.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Weight-adjusted-waist index as a mediator in the association between atherogenic index of plasma and obstructive sleep apnoea: insights from NHANES 2015-2020.Journal of health, population, and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDepression is associated with smoking and inflammation. However, whether inflammation and metabolic insulin resistance mediate the relationship between smoking and depression remains unclear.
methodsWe analyzed 15,391 participants from the 2005-2018 National Health and Nutrition Examination Survey (NHANES), representing approximately 92,321,194 individuals in the USA. Data on depressive symptoms (assessed by the Patient Health Questionnaire-9 [PHQ-9]), smoking (assessed via smoking questionnaire), and Systemic Immune-Inflammation Index (SII) and metabolic insulin resistance score (METS-IR) were evaluated. Additionally, the effect of smoking on all-cause mortality among individuals with depressive symptoms was assessed.
resultsWeighted logistic regression analysis showed that current smoking was significantly associated with a higher risk of depressive symptoms (OR = 3.02, 95% CI: 2.46-3.69, P < 0.001), with consistent findings across subgroups. Weighted generalized linear regression indicated that smoking upregulates SII and METS-IR levels. Specifically, current smokers had SII and METS-IR levels 86.1 (95% CI: 67.5-104.8) and 0.01 (95% CI: 0.005-0.02) units higher than never-smokers, respectively. Restricted cubic spline models demonstrated nonlinear dose-response relationships between SII, METS-IR, and depressive symptom severity (P for nonlinear < 0.05). SII and METS-IR mediated 0.69% and 0.86% of the relationship between smoking and depressive symptoms, respectively. Lastly, smoking appeared to increase all-cause mortality in individuals with depressive symptoms.
conclusionsThe positive association between smoking and depressive symptoms is partly mediated by SII and METS-IR. Smoking cessation may alleviate depressive symptoms and improve survival in individuals with depressive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.